<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2306222256
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VENEX XR 75MG CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VENLAFAXINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        75
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Modified-release capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        54.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PHARMATHEN INTERNATIONAL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PHARMATHEN INTERNATIONAL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AX16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Venex XR is an antidepressant that belongs to a group of medicines called serotonin and&nbsp;<br />norepinephrine reuptake inhibitors (SNRIs). This group of medicines is used to treat&nbsp;<br />depression and other conditions such as anxiety disorders. It is thought that people who&nbsp;<br />are depressed and/or anxious have lower levels of serotonin and noradrenaline in the&nbsp;<br />brain. It is not fully understood how antidepressants work, but they may help by&nbsp;<br />increasing the levels of serotonin and noradrenaline in the brain.&nbsp;<br />Venex XR is a treatment for adults with depression. Venex XR is also a treatment for&nbsp;<br />adults with social anxiety disorder (fear or avoidance of social situations). Treating&nbsp;<br />depression or social anxiety disorder properly is important to help you get better. If it is&nbsp;<br />not treated, your condition may not go away and may become more serious and more&nbsp;<br />difficult to treat.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Venex XR&nbsp;<br />&bull; If you are allergic to Venex XR or any of the other ingredients of Venex XR.&nbsp;<br />&bull; If you are also taking or have taken any time within the last 14 days any medicines&nbsp;<br />known as irreversible monoamine oxidase inhibitors (MAOIs), used to treat depression&nbsp;<br />or Parkinson&rsquo;s disease. Taking an irreversible MAOI together with other medicines,&nbsp;<br />including Venex XR, can cause serious or even life-threatening side effects. Also, you&nbsp;<br />must wait at least 7 days after you stop taking Venex XR before you take any MAOI&nbsp;<br />(see also the sections &ldquo;Serotonin syndrome&rdquo; and &ldquo;Taking other medicines&rdquo;).&nbsp;<br /><strong>Take special care with Venex XR&nbsp;</strong><br />&bull; If you use other medicines that taken concomitantly with Venex XR could increase the&nbsp;<br />risk of developing serotonin syndrome (see the section &ldquo;Taking other medicines&rdquo;).&nbsp;<br />&bull; If you have eye problems, such as certain kinds of glaucoma (increased pressure in the&nbsp;<br />eye).&nbsp;<br />&bull; If you have a history of high blood pressure.&nbsp;<br />&bull; If you have a history of heart problems.&nbsp;<br />&bull; If you have a history of fits (seizures).&nbsp;<br />&bull; If you have a history of low sodium levels in your blood (hyponatraemia).&nbsp;<br />&bull; If you have a tendency to develop bruises or a tendency to bleed easily (history of&nbsp;<br />bleeding disorders), or if you are taking other medicines that may increase the risk of&nbsp;<br />bleeding.&nbsp;</p><p>&bull; If your cholesterol levels get higher.&nbsp;<br />&bull; If you have a history of, or if someone in your family has had, mania or bipolar disorder&nbsp;<br />(feeling over-excited or euphoric).&nbsp;<br />&bull; If you have a history of aggressive behaviour.&nbsp;<br />Venex XR may cause a sensation of restlessness or an inability to sit or stand still. You&nbsp;<br />should tell your doctor if this happens to you.&nbsp;<br />If any of these conditions apply to you, please talk with your doctor before taking Venex&nbsp;<br />XR.<br />Thoughts of suicide and worsening of your depression or anxiety disorder&nbsp;<br />If you are depressed and/or have anxiety disorders, you can sometimes have thoughts of&nbsp;<br />harming or killing yourself. These may be increased when you first start taking&nbsp;<br />antidepressants, since these medicines all take time to work, usually about two weeks,&nbsp;<br />but sometimes longer.&nbsp;</p><p><strong>You may be more likely to think like this:&nbsp;</strong><br />&bull; If you have previously had thoughts about killing yourself or harming yourself.&nbsp;<br />&bull; If you are a young adult. Information from clinical trials has shown an increased risk of&nbsp;<br />suicidal behavior in young adults (less than 25 years old) with psychiatric conditions&nbsp;<br />who were treated with an antidepressant.&nbsp;<br />If you have thoughts of harming or killing yourself at any time, contact your doctor or&nbsp;<br />go to a hospital straight away.&nbsp;<br />You may find it helpful to tell a relative or close friend that you are depressed or have an&nbsp;<br />anxiety disorder, and ask them to read this leaflet. You might ask them to tell you if they&nbsp;<br />think your depression or anxiety is getting worse, or if they are worried about changes in&nbsp;<br />your behavior.&nbsp;<br />Diabetes: Your blood glucose levels may be altered due to VENEX XR. Therefore, the&nbsp;<br />dosage of your diabetes medicines may need to be adjusted.</p><p><strong>Dry mouth&nbsp;</strong><br />Dry mouth is reported in 10% of patients treated with Venex XR. This may increase the&nbsp;<br />risk of caries. Therefore, you should take special care in your dental hygiene.&nbsp;<br />Use in children and adolescents under 18 years of age&nbsp;<br />Venex XR should normally not be used for children and adolescents under 18 years.&nbsp;<br />Also, you should know that patients under 18 have an increased risk of side effects, such&nbsp;<br />as suicide attempt, suicidal thoughts and hostility (predominantly aggression,&nbsp;<br />oppositional behaviour and anger) when they take this class of medicines. Despite this,&nbsp;<br />your doctor may prescribe Venex XR for patients under 18 because he/she decides that&nbsp;this is in their best interests. If your doctor has prescribed Venex XR for a patient under&nbsp;<br />18, and you want to discuss this, please go back to your doctor. You should inform your&nbsp;<br />doctor if any of the symptoms listed above develop or worsen when patients under 18&nbsp;<br />are taking Venex XR. Also, the long-term safety effects concerning growth, maturation&nbsp;<br />and cognitive and behavioural development of Venex XR in this age group has not yet&nbsp;<br />been demonstrated.&nbsp;</p><p><strong>Taking other medicines&nbsp;</strong><br />Please tell your doctor or pharmacist if you are taking or have recently taken any other&nbsp;<br />medicines, including medicines obtained without a prescription.&nbsp;<br />Your doctor should decide whether you can take Venex XR with other medicines.&nbsp;<br />Do not start or stop taking any medicines, including those bought without a prescription,&nbsp;<br />natural and herbal remedies, before checking with your doctor or pharmacist.&nbsp;<br />&bull; Monoamine oxidase inhibitors (MAOIs: see the section &ldquo;Before you take Venex XR&rdquo;).&nbsp;<br />&bull; Serotonin syndrome:&nbsp;<br />Serotonin syndrome, a potentially life-threatening condition or Neuroleptic Malignant&nbsp;<br />Syndrome (NMS)-like reactions (see the section &ldquo;Possible Side Effects&rdquo;), may occur&nbsp;<br />with Venex XR treatment, particularly when taken with other medicines.&nbsp;</p><p><strong>Examples of these medicines include:&nbsp;</strong><br />&bull; Triptans (used for migraine)&nbsp;<br />&bull; Medicines to treat depression, for instance SNRI, SSRIs, tricyclics, or medicines&nbsp;<br />containing lithium.&nbsp;<br />&bull; Medicines containing linezolid, an antibiotic (used to treat infections).&nbsp;<br />&bull; Medicines containing moclobemide, a reversible MAOI (used to treat depression)&nbsp;<br />&bull; Medicines containing sibutramine (used for weight loss).&nbsp;<br />&bull; Medicines containing tramadol (a pain-killer).&nbsp;<br />&bull; Products containing St. John&rsquo;s Wort (also called Hypericum perforatum, a natural or&nbsp;<br />herbal remedy used to treat mild depression)&nbsp;<br />&bull; Products containing tryptophan (used for problems such as sleep and depression).&nbsp;<br />&bull; Antipsychotics (used to treat a disease with symptoms such as hearing, seeing or sensing&nbsp;<br />things which are not there, mistaken beliefs, unusual suspiciousness, unclear reasoning&nbsp;<br />and becoming withdrawn).&nbsp;<br />Signs and symptoms of serotonin syndrome may include a combination of the following:&nbsp;<br />restlessness, hallucinations, loss of coordination, fast heart beat, increased body&nbsp;<br />temperature, fast changes in blood pressure, overactive reflexes, diarrhoea, coma,&nbsp;<br />nausea, vomiting. Get medical care right away if you think serotonin syndrome is&nbsp;happening to you.&nbsp;<br />The following medicines may also interact with Venex XR and should be used with&nbsp;<br />caution. It is especially important to mention to your doctor or pharmacist if you are&nbsp;<br />taking medicines containing:&nbsp;<br />&bull; Ketoconazole (an antifungal medicine)&nbsp;<br />&bull; Haloperidol or risperidone (to treat psychiatric conditions)&nbsp;<br />&bull; Metoprolol (a beta blocker to treat high blood pressure and heart problems)&nbsp;<br /><strong>Taking Venex XR with food and drink&nbsp;</strong><br />Venex XR should be taken with food (see section 3 &ldquo;HOW TO TAKE Venex XR&rdquo;).&nbsp;<br />You should avoid alcohol while you are taking Venex XR.&nbsp;<br /><strong>Pregnancy and breast-feeding</strong>&nbsp;<br />Tell your doctor if you become pregnant, or you are trying to become pregnant. You&nbsp;<br />should use Venex XR only after discussing the potential benefits and the potential risks&nbsp;<br />to your unborn child with your doctor.&nbsp;<br />Make sure your midwife and/or doctor knows you are on Venex XR. When taken during&nbsp;<br />pregnancy, similar drugs (SSRIs) may increase the risk of serious condition in babies,&nbsp;<br />called persistent pulmonary hypertension of the newborn (PPHN), making the baby&nbsp;<br />breathe faster and appear bluish. These symptoms usually begin during the first 24 hours&nbsp;<br />after the baby is born. If this happens to your baby you should contact your midwife&nbsp;<br />and/or doctor immediately.&nbsp;<br />Venex XR passes into breast milk. There is a risk of an effect on the baby. Therefore,&nbsp;<br />you should discuss the matter with your doctor, and he/she will decide whether you&nbsp;<br />should stop breast-feeding or stop the therapy with Venex XR.&nbsp;<br /><strong>Driving and using machines&nbsp;</strong><br />Do not drive or use any tools or machines until you know how Venex XR affects you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Venex XR exactly as your doctor has told you. You should check with your&nbsp;<br />doctor or pharmacist if you are not sure.&nbsp;<br />The usual recommended starting dose for treatment of depression and social anxiety&nbsp;<br />disorder is 75 m g per day. The dose can be raised by your doctor gradually, and if&nbsp;<br />needed, even up to a maximum dose of 375 mg daily for depression. The maximum dose&nbsp;<br />for social anxiety disorder is 225 mg/day.&nbsp;<br />Take Venex XR at approximately the same time each day, either in the morning or in the&nbsp;<br />evening. Capsules must be swallowed whole with fluid and not opened, crushed, chewed&nbsp;or dissolved.&nbsp;<br /><strong>Venex XR should be taken with food.&nbsp;</strong><br />If you have liver or kidney problems, talk to your doctor, since your dose of Venex XR&nbsp;<br />may need to be different.&nbsp;<br />Do not stop taking Venex XR without talking to your doctor (see the section &ldquo;If you stop&nbsp;<br />taking Venex XR&rdquo;).&nbsp;<br /><strong>If you take more Venex XR than you should&nbsp;</strong><br />Call your doctor or pharmacist immediately if you take more than the amount of Venex&nbsp;<br />XR prescribed by your doctor.&nbsp;<br />The symptoms of a possible overdose may include a rapid heartbeat, changes in level of&nbsp;<br />alertness (ranging from sleepiness to coma), blurred vision, seizures or fits, and&nbsp;<br />vomiting.<br /><strong>If you forget to take Venex XR&nbsp;</strong><br />If you miss a dose, take it as soon as you remember. However, if it is time for your next&nbsp;<br />dose, skip the missed dose and take only a single dose as usual. Do not take more than&nbsp;<br />the daily amount of Venex XR that has been prescribed for you in one day.&nbsp;<br /><strong>If you stop taking Venex XR&nbsp;</strong><br />Do not stop taking your treatment or reduce the dose without the advice of your doctor&nbsp;<br />even if you feel better. If your doctor thinks that you no longer need Venex XR , he/she&nbsp;<br />may ask you to reduce your dose slowly before stopping treatment altogether. Side&nbsp;<br />effects are known to occur when people stop using Venex XR, especially when Venex&nbsp;<br />XR is stopped suddenly or the dose is reduced too quickly. Some patients may&nbsp;<br />experience symptoms such as tiredness, dizziness, light-headedness, headache,&nbsp;<br />sleeplessness, nightmares, dry mouth, loss of appetite, diarrhea, nervousness, agitation,&nbsp;<br />confusion, ringing in the ears, tingling or rarely electric shock sensations, weakness,&nbsp;<br />sweating, seizures, or flu-like symptoms.&nbsp;<br />Your doctor will advise you on how you should gradually discontinue Venex XR&nbsp;<br />treatment. If you experience any of these or other symptoms that are troublesome, ask&nbsp;<br />your doctor for further advice.&nbsp;<br />If you have any further questions on t he use of this product, ask your doctor or&nbsp;<br />pharmacist.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Venex XR can cause side effects, although not everybody gets them.&nbsp;<br />Allergic reactions&nbsp;</p><p>If any of the following happen, do not take more Venex XR. Tell your doctor&nbsp;<br />immediately, or go to the casualty department at your nearest hospital:&nbsp;<br />&bull; Chest tightness, wheezing, trouble swallowing or breathing&nbsp;<br />&bull; Swelling of the face, throat, hands, or feet&nbsp;<br />&bull; Feeling nervous or anxious, dizziness, throbbing sensations, sudden reddening of the&nbsp;<br />skin and/or a warm feeling&nbsp;<br />&bull; Severe rash, itching, or hives (elevated patches of red or pale skin that often itch)&nbsp;<br /><strong>Serious side effects&nbsp;</strong><br />If you notice any signs of the following, you may need urgent medical attention:&nbsp;<br />&bull; Heart problems, such as fast or irregular heart rate, increased blood pressure&nbsp;<br />&bull; Eye problems, such as blurred vision, dilated pupils&nbsp;<br />&bull; Nerve problems, such as dizziness, pins and needles, movement disorder, seizures or fits&nbsp;<br />&bull; Psychiatric problems, such as hyperactivity and euphoria&nbsp;<br />&bull; Treatment withdrawal (see the section &ldquo;HOW TO TAKE Venex XR, if you stop taking&nbsp;<br />Venex XR&rdquo;).&nbsp;<br /><strong>Complete side effect listing&nbsp;</strong><br />The frequency (likelihood of occurring) of side effects is classified as follows:&nbsp;<br />Very common :Affects more than 1 user in 10<br />Common: Affects 1 to 10 users in 100<br />Uncommon :Affects 1 to 10 users in 1,000<br />Rare :Affects 1 to 10 users in 10,000<br />Not known&nbsp; :Frequency cannot be estimated from&nbsp;<br />the available data<br />&bull; Blood disorders&nbsp;<br />Uncommon: bruising; black tarry stools (feces) or blood in stools, which can be a sign of&nbsp;<br />internal bleeding not known: reduced number of platelets in your blood, leading to an&nbsp;<br />increased risk of bruising or bleeding; blood disorders which may lead to an increased&nbsp;<br />risk of infection&nbsp;</p><p><strong>&bull; Metabolism/nutritional disorders&nbsp;</strong><br />Common: weight loss; increased cholesterol&nbsp;<br />Uncommon: weight gain&nbsp;<br />Not known: slight changes in blood levels of liver enzymes; decrease in blood sodium&nbsp;<br />levels; itchiness, yellow skin or eyes, dark urine, or flu-like symptoms, which are&nbsp;<br />symptoms of inflammation of the liver (hepatitis); confusion, excessive water intake&nbsp;<br />(known as SIADH); abnormal breast milk production&nbsp;<br /><strong>&bull; Nervous system disorders&nbsp;</strong><br />Very common: dry mouth; headache&nbsp;<br />Common: abnormal dreams; decreased libido; dizziness; increased muscle tonus;&nbsp;<br />insomnia; nervousness; pins and needles; sedation; tremor; confusion; feeling separated&nbsp;<br />(or detached) from yourself and reality Uncommon: lack of feeling or emotion;&nbsp;<br />hallucinations; involuntary movement of the muscles; agitation; impaired coordination&nbsp;<br />and balance&nbsp;<br />Rare: a sensation of restlessness or an inability to sit or stand still; seizures or fits;&nbsp;<br />feeling overexcited or euphoric&nbsp;<br />Not known: a high temperature with rigid muscles, confusion or agitation, and sweating,&nbsp;<br />or if you experience jerky muscle movements which you can&rsquo;t control, these may be&nbsp;<br />symptoms of serious conditions known as neuroleptic malignant syndrome; euphoric&nbsp;<br />feelings, drowsiness, sustained rapid eye movement, clumsiness, restlessness, feeling of&nbsp;<br />being drunk, sweating or rigid muscles, which are symptoms of serotonergic syndrome;&nbsp;<br />disorientation and confusion often accompanied by hallucination (delirium); stiffness,&nbsp;<br />spasms and involuntary movements of the muscles; thoughts of harming or killing&nbsp;<br />yourself&nbsp;<br /><strong>&bull; Sight and hearing disorders&nbsp;</strong><br />Common: blurred vision&nbsp;<br />Uncommon: altered taste sensation; ringing in the ears (tinnitus)&nbsp;<br />Not known: severe eye pain and decreased or blurred vision&nbsp;<br /><strong>&bull; Heart or circulation disorders&nbsp;</strong><br />Common: increase in blood pressure; flushing; palpitations&nbsp;<br />Uncommon: feeling dizzy (particularly when standing up too quickly), fainting, fast&nbsp;heartbeat&nbsp;<br />Not known: decrease in blood pressure; abnormal, rapid or irregular heartbeat, which&nbsp;<br />could lead to fainting&nbsp;<br /><strong>&bull; Breathing disorders</strong></p><p>Common: yawning&nbsp;<br />Not known: coughing, wheezing, shortness of breath and a high temperature, which are&nbsp;<br />symptoms of inflammation of the lungs associated with an increase in white blood cells&nbsp;<br />(pulmonary eosinophilia)&nbsp;<br /><strong>&bull; Digestive disorders&nbsp;</strong><br />Very common: nausea&nbsp;<br />Common: appetite decreased; constipation; vomiting&nbsp;<br />Uncommon: grinding of the teeth; diarrhea&nbsp;<br />Not known: severe abdominal or back pains (which could indicate a serious problem in&nbsp;<br />the gut, liver or pancreas)&nbsp;<br />&bull; <strong>Skin disorders&nbsp;</strong><br />Very common: sweating (including night sweats)&nbsp;<br />Uncommon: rash; abnormal hair loss&nbsp;<br />Not known: skin rash, which may lead to severe blistering and peeling of the skin;&nbsp;<br />itching; mild rash&nbsp;<br /><strong>&bull; Muscle disorders&nbsp;</strong><br />Not known: unexplained muscle pain, tenderness or weakness (rhabdomyolysis)&nbsp;<br /><strong>&bull; Urinary system disorders&nbsp;</strong><br />Common: difficulties passing urine; increased frequency in urination&nbsp;<br />Uncommon: inability to pass urine&nbsp;<br /><strong>&bull; Reproductive and sexual disorders&nbsp;</strong><br />Common: abnormal ejaculation/orgasm (males); lack of orgasm; erectile dysfunction&nbsp;<br />(impotence); menstrual irregularities such as increased bleeding or increased irregular&nbsp;<br />bleeding&nbsp;<br />Uncommon: abnormal orgasm (females)&nbsp;<br /><strong>&bull; General&nbsp;</strong><br />Common: weakness (asthenia); chills&nbsp;<br />Uncommon: sensitivity to sunlight&nbsp;<br />Not known: swollen face or tongue, shortness of breath or difficulty breathing, often&nbsp;<br />with skin rashes (this may be a serious allergic reaction)&nbsp;<br />Venex XR sometimes causes unwanted effects that you may not be aware of, such as&nbsp;<br />increases in blood pressure or abnormal heart beat; slight changes in blood levels or liver&nbsp;<br />enzymes, sodium or cholesterol. More rarely, Venex XR may reduce the function of&nbsp;<br />platelets in your blood, leading to an increased risk of bruising or bleeding. Therefore,&nbsp;<br />your doctor may wish to do blood tests occasionally, particularly if you have been taking&nbsp;Venex XR for a long time.&nbsp;<br />If any of the side effects gets serious, or if you notice any side effects not listed in this&nbsp;<br />leaflet, please tell your doctor or pharmacist.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.&nbsp;<br />Do not use Venex XR after the expiry date, which is stated on the packaging.&nbsp;<br />The expiry date refers to the last day of that month.&nbsp;<br />Store below 30&ordm;C.&nbsp;<br />Medicines should not be disposed of via wastewater or household waste. Ask your&nbsp;<br />pharmacist how to dispose of medicines no longer required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Venex XR contains&nbsp;<br />The active substance is Venlafaxine.&nbsp;<br />Each prolonged-release capsule, hard contains 75 m g and 150 m g of Venex&nbsp;<br />XR as venlafaxine hydrochloride.&nbsp;<br />The other ingredients are:<br />75 mg prolonged-release capsules, hard:<br />Capsule content: Hydromellose (Methocel K 100M), Eudragit RS 100 powder, Sodium&nbsp;<br />lauryl sulphate, Magnesium stearate<br />Coating: Eudragit E 100&nbsp;<br />Capsule shell: Titanium Dioxide E 171, Iron Oxide (Red) E172, Gelatin&nbsp;<br />150 mg prolonged-release capsules, hard:<br />Capsule content: Hydromellose (Methocel K 100M), Eudragit RS 100 powder, Sodium&nbsp;<br />lauryl sulphate, Magnesium stearate<br />Coating: Eudragit E 100&nbsp;<br />Capsule shell: Titanium Dioxide E 171, Erythrosine E 127, Indigo Carmine E132,&nbsp;<br />Gelatin<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                75 mg prolonged-release capsules, hard: flesh opaque – flesh opaque size 0 hard gelatin 
capsules containing 75 mg Venlafaxine. 
150 mg prolonged-release capsules, hard: scarlet opaque – scarlet opaque size 00 hard 
gelatin capsules containing 150 mg Venlafaxine. 
Pack sizes: Pack sizes 2×blister of 7 cap

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO</p><p>AlQassim pharmaceutical plant</p><p>Saudi Pharmaceutical Industries &amp; Medical Appliance Corporation.</p><p>Saudi Arabia<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in November 2012
 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>1 .ما هى أقراص فينيكس م.م. وفيم تستخدم :<br />فينيكس م.م. هو دواء مضاد للاكتئاب، وهو ينتمى إلى مجموعة من الأدوية تعرف باسم مثبطات امتصاص السيروتونين&nbsp;والنورإبينيفرين (SNRIs)&nbsp;.تستخدم هذه المجموعة من الأدوية لعلاج الاكتئاب وبعض الحالات الأخرى مثل اضطرابات&nbsp;القلق. حيث أنه يعتقد أن الأشخاص المصابين بالاكتئاب و/ أو القلق لديهم مستويات منخفض من السيروتونين والنورأدرينالين&nbsp;<br />بالمخ. كيفية عمل مضادات الاكتئاب ليست مفهومة بالشكل الكامل، لكنها قد تساعد عن طريق زيادة مستويات السيروتونين&nbsp;والنورأدرينالين بالمخ.<br />فينيكس م.م. يستخدم لعلاج الأشخاص البالغين المصابين بالاكتئاب. فينيكس م.م. يستخدم أيضا لعلاج الأشخاص البالغين&nbsp;المصابين باضطرابات القلق الاجتماعى (الخوف من أو تجنب المواقف الاجتماعية). من المهم علاج الاكتئاب واضطرابات&nbsp;<br />القلق الاجتماعى بشكل سليم لتساعدك على الشعور بتحسن. فى حالة عدم العلاج قد تسوء حالتك أكثر من ذى قبل وتصبح&nbsp;أكثر صعوبة وقد لاتشفى أبدا.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>امتنع عن تناول أقراص فينيكس م.م. وأخبر طبيبك فى الحالات الآتية:<br />&bull; إذا كنت تعاني من فرط التحسس لفينيكس م.م.، أو أى من المكونات الأخرى لفينيكس م.م..<br />&bull; إذا كنت تتناول حاليا أو فى خلال فترة ال 14 يوم السابقة أيا من الأدوية التى تعرف باسم المثبطات اللاعكسية لإنزيم مونو&nbsp;أمين أوكسيديز ( MAOIs)&nbsp;،والتى تستخدم لعلاج الاكتئاب أومرض باركنسون. تناول المثبطات اللاعكسية لإنزيم مونو&nbsp;أمين أكسيديز (MAOIs) مع بعض الأدوية الأخرى، وتشمل فينيكس م.م. قد يسبب أعراض جانبية خطيرة وقد يهدد الحياة.&nbsp;<br />أيضا يجب عليك أن تنتظر لمدة لا تقل عن 7 أيام بعد التوقف عن تناول فينيكس م.م. قبل البدء فى تناول أيا من مثبطات إنزيم&nbsp;مونو أمين أوكسيديز (انظر أيضا إلى الفقرتين &laquo;متلازمة السيروتونين&raquo; و &laquo;تناول بعض الأدوية الأخرى&raquo;).</p><p><strong>ينبغى توخى الحذر عند تناول أقراص فينيكس م.م. فى الحلات الآتية</strong>:<br />&bull; إذا كنت تتناول بعض الأدوية الأخرى والتى عندما تؤخذ بصورة متزامنة مع فينيكس م.م. قد تزيد من خطورة وضع متلازمة&nbsp;<br />السيروتونين (فضلا انظر إلى فقرة &laquo; تناول بعض الأدوية الأخرى&raquo;).<br />&bull; إذا كنت تعانى من مشاكل فى العين مثل بعض أنواع الجلوكوما (زيادة الضغط داخل العين).<br />&bull; إذا كان لديك تاريخ من ضغط الدم المرتفع.<br />&bull; إذا كان لديك تاريخ من مشاكل بالقلب.<br />&bull; إذا كان لديك تاريخ من نوبات الصرع.<br />&bull; إذا كان لديك تاريخ من انخفاض مستوى الصوديوم بالدم (هيبوناتريميا).<br />&bull; إذا كانت لديك قابلية تكوين كدمات أو قابلية النزف بسهولة ( اضطرابات النزف)، أو أنك تتناول أدوية أخرى تزيد من&nbsp;<br />خطورة إصلبتك بالنزيف.<br />&bull; إذا ارتفع مستوى الكوليستيرول بالدم لديك.<br />&bull; إذا كان لديك تاريخ أو فرد من أفراد أسرتك قد عانى من الهوس أو الاضطراب الثنائي القطب (الشعور بالإثارة المفرطة أو&nbsp;<br />الحماسية).<br />&bull; إذا كان لديك تاريخ من السلوك العدوانى.</p><p><br />فينيكس م.م. قد يتسبب فى الشعور بعدم الارتياح أو عدم القدرة على الجلوس أو الوقوف بسكون. يجب عليك إخبار الطبيب&nbsp;إذا حدث لك ذلك.</p><p>إذا انطبقت عليك أي من هذه الحالات، فضلا تواصل مع طبيبك قبل تناول فينيكس م.م..<br />التفكير في الانتحار وازدياد سوء حالة الاكتئاب أو اضطراب القلق</p><p>إذا كنت مصابا بالاكتئاب و/ أو اضطرابات القلق، فإنه قد تراودك أحيانا بعض الأفكار لإيذاء أو قتل نفسك. والتى قد تزداد&nbsp;عند تناولك لمضادات الاكتئاب للمرة الأولى، حيث أن هذه الأدوية تستغرق وقتا لكى تعمل، عادة حوالى أسبوعين، وربما&nbsp;أكثر فى بعض الأحيان.&nbsp;<br /><strong>قد تكون أكثر عرضة للتفكير هكذا فى الحالات الاتية:</strong><br />&bull; إذا كانت تلك الأفكار عن قتل أو إيذاء نفسك قد راودتك من قبل.<br />&bull; إذا كنت بالغا صغير السن. حيث أن المعلومات من التجارب السريرية تفيد بزيادة خطورة سلوك الانتحار لدى البالغين صغار&nbsp;<br />السن (أقل من عمر 25 سنة) المصابين بحالات نفسية وتعرضوا للعلاج بمضادات الاكتئاب.<br />إذا راوتك أفكار عن إيذاء أو قتل نفسك فى أى وقت، تواصل مع طبيبك أو اذهب فورا إلى المستشفى.<br />قد يكون من المفيد أن تخبر قريبا لك أو صديق مقرب إليك بأنك مصابا بالاكتئاب أو اضطراب القلق، وتسألهم لقراءة هذه&nbsp;<br />النشرة. قد تسألهم أيضا ليخبروك إذا ظنوا أن حالة الاكتئاب أو القلق لديك تزداد سوء، أو لو أنهم قلقين من التغير فى سلوكك.<br />في حالة مرضى السكر: قد تضطرب مستويات السكر في الدم عند تناول فينيكس م.م. ، لذلك يتوجب عليك تعديل جرعة&nbsp;<br />دواء السكر التي تتناولها أثناء تناولك لفينيكس م.م.<br /><strong>جفاف الفم</strong><br />جفاف الفم مسجل فى 10 %من المرضى المعالجين بفينيكس م.م. والذى قد يزيد من خطورة التسوس، لذا يجب عليك&nbsp;<br />الاعتناء الخاص بنظافة أسنانك.<br /><strong>الاستخدام للأطفال والبالغين أقل من سن 18 سنة:</strong><br />فينيكس م.م. لا يستخدم عادة للأطفال والبالغين أقل من سن 18 سنة. أيضا يجب عليك أن تعلم أن المرضى أقل سنا من 18سنة أكثر عرضة للأعراض الجانبية، مثل محاولة الانتحار، أفكار الانتحار والعدوانية (فى الغالب سلوك العداء والمعارضة&nbsp;والغضب) عند تعرضهم للعلاج بهذه المجموعة من الأدوية. بالرغم من ذلك قد يلجأ طبيبك فى بعض الأحيان إلى وصف&nbsp;فينيكس م.م. للمرضى الأقل سنا من 18 سنة إذا قرر أن ذلك سيكون فى مصلحتهم. إذا قام طبيبك بوصف فينيكس م.م.&nbsp;لمريض أقل سنا من 18 سنة وأنت تود مناقشة ذلك، فضلا ارجع إلى طبيبك. يجب عليك إخبار طبيبك فى حالة ظهور أو&nbsp;ازدياد سوء أى من الأعراض السابق ذكرها أعلاه للمرضى الأقل سنا من 18 سنة عند تناولهم لفينيكس م.م. أيضا&nbsp;آثار السلامة طويلة الأجل بشأن النمو، والنضج والتنمية المعرفية والسلوكية لفينيكس م.م. في هذه الفئة العمرية لم يتم إثباته&nbsp;<br />حتى الآن.<br /><strong>تناول أدوية أخرى</strong><br />يرجى إخبار الطبيب أو الصيدلي إذا كنت تأخذ أو أخذت في الآونة الأخيرة أي أدوية أخرى، بما في ذلك الأدوية التي تم&nbsp;<br />الحصول عليها دون وصفة طبية.<br />وينبغي على الطبيب أن يقرر ما إذا كان بإمكانك أن تأخذ فينيكس م.م. مع أدوية أخرى.<br />لا تبدأ بتناول أو التوقف عن تناول أي أدوية، بما فيها تلك التي حصلت عليها من دون وصفة طبية، العلاجات الطبيعية&nbsp;والعشبية، قبل التحقق مع طبيبك أو الصيدلي.<br />&bull; مثبطات إنزيم مونو أمين أكسيديز ( MAOIs انظر الفقرة &laquo; ما يجب مراعاته قبل تناول أقراص فينيكس م.م. متلازمة&nbsp;<br />السيروتونين:<br />متلازمة السيروتونين، وهى حالة خطرة تهدد الحياه أو تتسبب في تفاعلات شبيهة بالمتلازمة الخبيثة للدواء المضاد للذهان&nbsp;<br />(انظر فقرة &laquo;أعراض جانبية محتملة الحدوث&raquo;) من الممكن أن تحدث مع استخدام فينيكس م.م. خاصة عند تناوله مع بعض&nbsp;<br />الأدوية الأخرى مثل:<br />&bull; تريبتانز (والتى تستخدم لعلاج الصداع النصفى).<br />&bull; أدوية تستخدم لعلاج الاكتئاب، مثل SNRIs ،SSRIs ،ترايسيكليات، أو الأدوية التى تحتوى على الليثيوم.<br />&bull; الأدوية التى تحتوى على لاينزوليد، وهو مضاد حيوى (يستخدم لعلاج العدوى البكتيرية)</p><p>&bull; الأدوية التى تحتوى على موكلوبيميد، وهو مثبط عكسى لإنزيم مونو أمين أكسيديز(يستخدم لعلاج الاكتئاب).<br />&bull; الأدوية التى تحتوى على سيبوترامين (وهو يستخدم لإنقاص الوزن).<br />&bull; الأدوية التى تحتوى على ترامادول (وهو قاتل للألم).<br />&bull; الأدوية التى تحتوى على عشبة القديس جون (والتى تعرف أيضا باسم عشبة بيرفوراتم، وهى علاج طبيعي أو عشبى يستخدم&nbsp;<br />في علاج الاكتئاب الخفيف).<br />&bull; الأدوية التي تحتوي على التربتوفان (التي تستخدم لعلاج بعض المشاكل مثل النوم والاكتئاب).<br />&bull; مضادات الذهان ( وهي أدوية تستخدم في علاج المرضى الذين يشعرون بأنهم يسمعون، أو يرون أو يلمسون أشياء غير&nbsp;<br />موجودة، أو تظهر عندهم أفكار غير منطقية أو يعنون من حالة الشك الغير طبيعي، أو يعانون من التفكير غير الواضح أو&nbsp;<br />الانسحاب.<br />علامات وأعراض متلازمة السيروتونين ربما تشتمل على مجموعة من الأعراض التالية: الأرق، والهلوسة، وفقدان&nbsp;<br />التنسيق، ضربات القلب السريعة، وزيادة درجة حرارة الجسم، والتغيرات السريعة في ضغط الدم، وردود الأفعال المفرطة،&nbsp;<br />والإسهال، والغيبوبة والغثيان والقيء.<br />الأدوية التالية أيضا قد تتفاعل مع فينيكس م.م. ويجب أن تستخدم بحرص. من المهم بصفة خاصة أن تخبر طبيبك أو&nbsp;<br />الصيدلي إذا كنت تتناول الأدوية التي تحتوي على:<br />&bull; كيتوكونازول (وهو دواء مضاد للفطريات).<br />&bull; هالوبيريدول أو ريسبيريدون (والتى تستخدم لعلاج الحالات النفسية).<br />&bull; ميتوبرولول ( وهو مثبط لمستقبلات بيتا ويستخدم لعلاج ارتفاع ضغط الدم ومشاكل القلب).<br /><strong>تناول فينيكس م.م. مع الطعام والشراب:</strong><br />يجب تناول فينيكس م.م. مع الطعام (انظر الفقرة 3&raquo; طريقة استخدام فينيكس م.م. &laquo;). تجنب تناول الكحول أثناء تناولك&nbsp;<br />لفينيكس م.م.<br /><strong>الحمل والرضاعة:</strong><br />يجب عليك إخبار طبيبك إذا أصبحت حاملا، أو تحاولى أن تصبحى حاملا. يجب عليك استخدام فينيكس م.م. فقط بعد مناقشة&nbsp;<br />الفوائد المحتملة والمخاطر المحتملة على الجنين مع طبيبك.<br />تأكدى من إخبار ممرضة التوليد و/ أو الطبيب بأنك تخضعى للعلاج بفينيكس م.م. عند الاستخدام خلال فترة الحمل، الأدوية&nbsp;<br />المشابهة (SSRIs (قد تزيد من مخاطر حالة خطيرة في الأطفال، وتسمى ارتفاع ضغط الدم الرئوي المستمر عند المولود&nbsp;<br />(PPHN ،(مما يجعل الطفل يتنفس بشكل أسرع، ويبدو مزرقا. هذه الأعراض تبدأ عادة خلال ال 24 ساعة الأولى بعد ولادة&nbsp;<br />الطفل. فى حالة حدوث ذلك لطفلك يجب عليك الاتصال بممرضة التوليد و / أو الطبيب فورا.<br />فينيكس م.م. يمر إلى حليب الأم. مما قد يسبب خطورة فى التأثير على الجنين. ولذلك، يجب مناقشة هذه المسألة مع الطبيب،&nbsp;<br />وأنه / أنها سوف يقرر ما إذا كان يجب عليك التوقف عن الرضاعة الطبيعية أو وقف العلاج بفينيكس م.م.<br /><strong>القيادة واستخدام الآلات</strong>&nbsp;<br />لا تقود أو تستخدم أي أدوات أو آلات حتى تعرف كيفية تأثير فينيكس م.م. عليك.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم دائما بتناول فينيكس م.م. كما أخبرك طبيبك المعالج بالضبط. يجب أن تحقق مع الطبيب أو الصيدلي إذا كنت غير متأكد.<br />جرعة البداية الموصى بها عادة لعلاج الاكتئاب واضطراب القلق الاجتماعي هو 75 ملجم في اليوم الواحد. ويمكن رفع&nbsp;<br />الجرعة من قبل الطبيب تدريجيا، وإذا لزم الأمر، حتى تصل إلى الجرعة القصوى وهى 375 ملجم يوميا لعلاج الاكتئاب.&nbsp;<br />الجرعة القصوى لعلاج اضطراب القلق الاجتماعي هي 225 ملجم يوميا.</p><p>تناول فينيكس م.م. فى نفس الوقت يوميا فى الصباح أو فى المساء.يجب بلع الكبسولة بشكل كامل مع سوائل دون طحن أو&nbsp;كسر أو فتح أو مضغ.<br />ينصح بتناول فينيكس م.م. مع الأكل.<br />إذا كنت تعانى من مشاكل فى الكلية أو فى الكبد أخبر الطبيب حيث أن جرعة فينيكس م.م. قد تحتاج إلى تعديل.<br />لا تتوقف عن تناول فينيكس م.م. دون استشارة الطبيب.(انظر فقرة التوقف عن تناول فينيكس م.م.).<br /><strong>عند تناول جرعة زائدة من فينيكس م.م.:</strong><br />اتصل بالطبيب أو بالصيدلى فورا اذا تناولت كمية من فينيكس م.م. أكبر مما وصف لك الطبيب.<br />تتفاوت أعراض الجرعة الزائدة من فينيكس م.م. من زيادة فى ضربات القلب إلى اختلاف فى مستوى اليقظة (من النعاس إلى&nbsp;الغيبوبة) و عدم وضوح الرؤية والنوبات والقيئ.<br /><strong>عند نسيات تناول جرعة فينيكس م.م.:</strong><br />اذا نسيت تناول جرعة فينيكس م.م. تناولها عندما تتذكر ولكن اذا جاء موعد الجرعة التالية لا تتناول الجرعة المنسية وتناول&nbsp;<br />الجرعة التى تليها فى موعدها. لا تتناول اكثر من الجرعة اليومية الموصوفة لك من الطبيب.<br /><strong>التوقف عن تناول فينيكس م.م.:</strong><br />لا تتوقف عن تناول فينيكس م.م. أو تقلل الجرعة بدون استشارة الطبيب حتى عندما تتحسن حالتك.اذا رأى طبيبك أنك لا&nbsp;تحتاج فينيكس م.م. سوف يخبرك بتقليل الجرعة ببطئ قبل أن تتوقف عن تناول العلاج تماما.<br />يحدث أعراض جانية اذا توقفت عن تناول فينيكس م.م. خصوصا اذا حدث ذلك بصورة مفاجئة أو قللت الجرعة بشكل أسرع&nbsp;من اللازم.وتتفاوت هذه الأعراض من الإرهاق والدوار و الصداع و النعاس و الكوابيس و جفاف الفم و فقدان الشهية و&nbsp;الغثيان و الإسهال والتوتر و الهياج و الارتباك و صوت رنين فى الأذن و وخز ونادرا شعور بصدمات كهربائية وضعف&nbsp;وتعرق و نوبات وأعراض تشبه الإنفلونزا.<br />سوف يرشدك الطبيب الى كيفية ايقاف الدواء بصورة تدريجية.اذا تعرضت لأى من هذه الأعراض استشر طبيبك.<br />اذا كان لديك أى سؤال استشر طبيبك.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية قد يسبب فينيكس م.م. أعراض جانبية مع أنها لا تصيب كل المرضى مثل:<br />الحساسية:<br />اذا حدث لك أى من الأعرض التالية توقف عن تناول فينيكس م.م. واتصل بطبيك فورا أو توجه إلى أقرب مستشفى.<br />- ضيق فى الصدر أو صفير أو صعوبة فى البلع والتنفس.<br />- انتفاخ فى الوجه أو اليدين أو الحلق أو القدمين.<br />- الشعور بالقلق والدوار والتوتر و الخفقان و احمرار مفاجئ فى الجلد مع أو بدون دفئ.<br />- حكة مزمنة أو طفح جلدى.<br />أعراض جانية خطيرة:<br />اذا لاحظت أى من هذه الأعراض التالية ربما تحتاج لرعاية طبية عاجلة:<br />- مشاكل فى القلب مثل ارتفاع وعدم انتظام ضربات القلب وارتفاع ضغط الدم.<br />- مشاكل العين مثل عدم وضوح الرؤية واتساع حدقة العين.<br />- مشاكل عصبية مثل الدوار والوخز و اضطراب فى الحركة و النوبات .<br />- مشاكل نفسية مثل زيادة مفرطة فى الحركة و شعور بالنشوة.<br />- أعراض انسحاب الدواء ( انظر فقرة طريقة استخدام فينيكس م.م.&nbsp;</p><p>القائمة الكاملة للأعراض الجانبية:<br />يتم تصنيف احتمالية حدوث أعراض جانبية كما يلى:<br />يؤثر فى اكثر من 1 من 10 أشخاص. شائع جدا<br />يؤثر فى من 1 إلى 10 أشخاص فى 100 شخص. شائع<br />يؤثر فى من 1 إلى 10 أشخاص فى 1000 شخص. غير شائع<br />يؤثر فى من 1 إلى 10 أشخاص فى 10000 شخص. نادر<br />لا يمكن تحديد الإحتمالية فى ضوء المعلومات المتاحة. غير معلوم</p><p>&nbsp;</p><p><strong>اضطرابات فى الدم:</strong><br />غير شائع : كدمات و براز أسود قطرانى أو دم فى البراز ربما يكون علامة على وجود نزيف فى الأمعاء.<br />غير معلوم : نقص عدد الصفائح الدموية فى الدم مما يزيد من خطورة الكدمات و النزيف واضطرابات الدم مما يؤدى إلى&nbsp;<br />زيادة احتمالية الإصابة بالعدوى.<br /><strong>اضطرابات فى التغذية والأيض:</strong><br />شائع : فقدان الوزن و زيادة الكوليستيرول.<br />غير شائع : زيادة فى الوزن.<br />غير معلوم: تغيير طفيف فى مستوى انزيمات الكبد فى الدم و نقص فى مستوى الصوديوم فى الدم و حكة واصفرار فى الجلد&nbsp;<br />والعين و يصبح لون البول قاتم أو أعراض تشبه الانفلونزا وهى أعراض حدوث التهاب فى الكبد و ارتباك و زيادة فى تناول&nbsp;<br />الماء المعروف ب (أعراض زيادة افراز هرمون المضاد لادرار البول) و زيادة غير طبيعية فى افراز حليب الثدى.<br /><strong>اضطرابات فى الجهاز العصبى:</strong><br />شائع جدا : جفاف الفم و صداع.<br />شائع : أحلام غير عادية و انخفاض الرغبة الجنسية و دوار وزيادة فى حركة العضلات و أرق و عصبية ووخز و سكون و&nbsp;<br />ارتعاش و ارتباك و شعور بالانفصال عن النفس و الواقع.<br />غير شائع : نقص فى الإحساس والمشاعر و هلوسة و حركة لاارادية للعضلات وهياج و خلل فى التوازن.<br />نادر: شعور بعدم الراحة و عدم القدرة على الوقوف أو الجلوس لمدة و نوبات وشعور بزيادة فى الحماس والنشوة.<br />غير معلوم : ارتفاع فى درجة الحرارة مع تصلب للعضلات و ارتباك أو هياج و تعرق .اذا واجهتك حركات تشنجية&nbsp;<br />بالعضلات لا يمكن التحم بها ربما تكون هذه أعراض لحالة خطيرة معروفة بمتلازمة الزهان الخبيث.<br />شعور بالنشوة و النعاس وحركة سريعة مستمرة بالعين و الحماقات وعدم الراحة والتعرق و تصلب العضلات وهى أعراض&nbsp;<br />متلازمة السيروتونين.<br />توهان و ارتباك مصاحب بالهلوسة و التصلب والتقلصات وحركات لاارادية للعضلات وافكار بايذاء أو قتل النفس.<br /><strong>اضطرابات فى الرؤية والسمع :</strong><br />شائع : عدم وضوح فى الرؤية</p><p>غير شائع : اختلال فى حاسة التذوق و طنين فى الأذن.<br />غير معلوم : ألم شديد فى العين و عدم وضوح الرؤية ونقصها.<br /><strong>اضطرابات فى القلب والدورة الدموية:</strong><br />شائع : زيادة فى ضغط الدم و احمرار فى الوجه و خفقان.<br />غير شائع : الشعور بالدوار(خصوصا عند الوقوف بسرعه) وسرعة فى ضربات القلب و اغماء.<br />غير معلوم : هبوط فى ضغط الدم و زيادة وعدم انتظام غير طبيعى فى ضربات القلب مما قد يسبب اغماء.<br /><strong>اضطرابات فى التنفس:</strong><br />شائع : تثاؤب.<br />غير معلوم: كحه و عطس و قصر فى النفس وارتفاع فى درجة الحرارة وهى أعراض التهاب فى الرئة مصحوبة بزيادة فى&nbsp;<br />كرات الدم البيضاء (الإيزينوفيليا الرئوية).<br /><strong>أضطرابات فى الهضم :</strong><br />شائع جدا : غثيان.<br />شائع : نقص فى الشهيه و امساك و قيئ.<br />غير شائع : صرير الأسنان و اسهال.<br />غير معلوم : ألم حاد فى البطن والظهر (مما يوضح وجود مشكلة فى الجهاز الهضمى والكبد أوالبنكرياس).<br /><strong>اضطرابات فى الجلد :</strong><br />شائع جدا : العرق (العرق الليلى).<br />غير شائع : حكه و تساقط غير طبيعى للشعر.<br />غير معلوم : حكه فى الجلد مما قد يؤدى إلى ظهور تقرحات حاده وتقشير فى الجلد.<br />ا<strong>ضطرابات فى العضلات :</strong><br />غير معلوم : ألم غير مبرر فى العضلات و ضعف فى العضلات (انحلال الربيدات).<br />ا<strong>ضطرابات فى الجهاز البولى</strong> :<br />شائع : صعوبة فى التبول وزيادة فى عدد مرات التبول.<br />غير شائع : عدم قدرة على التبول.<br /><strong>اضطرابات فى الجهاز التناسلى:</strong><br />شائع : قذف و نشوة غير طبيعية (للرجال) ونقص فى النشوة و عدم القدرة على الانتصاب (ضعف جنسى).<br />اضطرابات فى الدورة الشهرية مثل زيادة فى الدم و نزيف غير طبيعى.<br />غير شائع : شهوة غير طبيعية (للنساء).<br /><strong>اضطرابات عامة:</strong><br />شائع : ضعف و خمول و قشعريرة.<br />غير شائع : حساسية لضوء الشمس.<br />غير معلوم: تورم الوجه أو اللسان و نقص النفس وصعوبة فى التنفس غالبا مع حساسية فى الجلد (وهذا قد يكون تفاعل&nbsp;<br />للحساسية).<br />فينيكس م.م. احيانا يسبب أعراض غير مرغوبة لا تعلمها مثل زيادة فى ضغط الدم و خفقان غير طبيعى للقلب.أو تغيرات&nbsp;<br />طفيفة فى مستويات ادم أو انزيمات الكبد أو الصوديوم أو الكوليستيرول.و نادرا قد يقلل فينيكس م.م. من وظائف الصفائح&nbsp;<br />الدموية فى الدم مما قد يؤدى إلى زيادة احتمالية حدوث كدمات أو نزيف.ولذلك قد ينصحك طبيبك بعمل تحاليل للدم من أن&nbsp;لأخر خصوصا إذا كنت ستأخذ فينيكس م.م. لمده طويله.<br />إذا حدث أى تأثير غير مرغوب فيه غير مذكور فضلا اخبر طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ بعيدا عن متناول الأطفال.<br />لا تستخدم فينيكس م.م. بعد انتهاء الصلاحية المذكورة على العلبة.<br />انتهاء الصلاحية يرمز إلى اخر يوم فى الشهر المذكور على العلبة.<br />احفظ فى درجة حرارة تحت 30درجة<br />لا ينبغى التخلص من الأدوية مع مياه الصرف أو مع النفايات المنزلية.اسال الصيدلى عن كيفية التخلص من الأدوية الغير&nbsp;مستخدمة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>الماده الفعاله هى فينلافاكسين.<br />كل كبسولة صلبة ممتدة المفعول تحتوى على 150 مجم و 75 مجم من فينيكس م.م. ك فينلافاكسين هيدروكلورايد.<br />المكونات الأخرى هى :<br />75 مجم كبسولات صلبة ممتدة المفعول :<br />تحتوى الكبسولة على : هيبروميللوز (ميثوسيل ك 100 م) بودرة يودراجيت أر أس 100 و صوديوم لوريل سلفات&nbsp;<br />وستياريت ماغنسيوم.<br />الغلاف : يودراجيت إى .100<br />قشرة الكبسولة : تيتانيوم ثنائى الأوكسيد إى 171 و أوكسيد الحديد (أحمر) إى 172 و جيلاتين.</p><p><br />150 مجم كبسولات صلبة ممتدة المفعول :<br />تحتوى الكبسولة على : هيبروميللوز (ميثوسيل ك 100 م) بودرة يودراجيت أر أس 100 و صوديوم لوريل سلفات&nbsp;<br />وستياريت ماغنسيوم.<br />الغلاف : يودراجيت إى .100<br />قشرة الكبسولة : تيتانيوم ثنائى الأوكسيد إى 171 و اريثروسين إى 127 و انديجو كارمين إى 132 و جيلاتي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>75 مجم كبسولات صلبة ممتدة المفعول: فليش اوباكيو-كبسولات فليش اوباكيو حجم 0 من الجيلاتين الصلب.<br />تحتوي 75 مجم فينلافاكسين.</p><p><br />150مجم كبسولات صلبة ممتدة المفعول: سكارليت اوباكيو-كبسولات سكاريت اوباكيو حجم 00 من الجيلاتين الصلب&nbsp;<br />تحتوي على 150 مجم فينلافاكسين.</p><p>حجم العبوة:<br />2 شريط مكون من 7 كبسولات&nbsp;&nbsp;.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إﻧﺘﺎج اﻟﺪواﺋﯿﺔ</p><p>ﻣﺼﻨﻊ اﻷدوﯾﺔ ﺑﺎﻟﻘﺼﯿﻢ،</p><p>اﻟﺸﺮﻛﺔ اﻟﺴﻌﻮدﯾﺔ ﻟﻠﺼﻨﺎﻋﺎت اﻟﺪواﺋﯿﺔ واﻟﻤﺴﺘﻠﺰﻣﺎت اﻟﻄﺒﯿﺔ،</p><p>اﻟﻤﻤﻠﻜﺔ اﻟﻌﺮﺑﯿﺔ اﻟﺴﻌﻮدﯾﺔ.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ﺗﻢ اﻟﻤﻮاﻓﻘﺔ ﻋﻠﻰ ھﺬه اﻟﻨﺸﺮة ﺑﺘﺎرﯾﺦ: نوفمبر 2012
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 [Venex] 75 mg hard prolonged-release capsules. 
 [Venex] 150 mg hard prolonged-release capsules.  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One prolonged-release capsule, hard contains venlafaxine hydrochloride equivalent to 75 mg and 150 mg of venlafaxine. 
For a full list of excipients, see section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged-release capsule, hard. 

Warning:
 Suicidality and Antidepressant Drugs   Antidepressants increased the risk compared to placebo of suicidal  thinking and behavior (suicidality) in children, adolescents, and young  adults in short-term studies of Major Depressive Disorder (MDD) and  other psychiatric disorders. Anyone considering the use of Venex  XR  or any other antidepressant in a child, adolescent, or young adult must  balance this risk with the clinical need. Short-term studies did not show  an increase in the risk of suicidality with antidepressants compared to  placebo in adults beyond age 24; there was a reduction in risk with  antidepressants compared to placebo in adults aged 65 and older.  Depression and certain other psychiatric disorders are themselves  associated with increases in the risk of suicide. Patients of all ages  who are started on antidepressant therapy should be monitored 
 appropriately and observed closely for clinical worsening, suicidality,  or unusual changes in behavior. Families and caregivers should be  advised of the need for close observation and communication with the  prescriber. Venex XR is not approved for use in pediatric patients.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of major depressive episodes.&nbsp;<br />For prevention of recurrence of major depressive episodes. &nbsp;<br />&nbsp;Treatment of social anxiety disorder</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Major depressive episodes</strong><br />The recommended starting dose for prolonged-release venlafaxine is 75 mg given once daily. Patients&nbsp;<br />not responding to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose of&nbsp;375 mg/day. Dosage increases can be made at intervals of 2 weeks or more. If clinically warranted due&nbsp;<br />to symptom severity, dose increases can be made at more frequent intervals, but not less than 4 days.&nbsp;<br />Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical&nbsp;<br />evaluation (see section 4.4). The lowest effective dose should be maintained.&nbsp;<br />Patients should be treated for a sufficient period of time, usually several months or longer. Treatment&nbsp;<br />should be reassessed regularly on a case-by-case basis. Longer-term treatment may also be appropriate&nbsp;<br />for prevention of recurrence of major depressive episodes (MDE). In most of the cases, the&nbsp;<br />recommended dose in prevention of recurrence of MDE is the same as the one used during the current&nbsp;<br />episode.&nbsp;<br />Antidepressive medicinal products should continue for at least six months following remission</p><p>&nbsp;</p><p><strong>Social anxiety disorder</strong><br />The recommended dose for prolonged-release venlafaxine is 75 mg given once daily. There is no&nbsp;<br />evidence that higher doses confer any additional benefit.&nbsp;<br />However, in individual patients not responding to the initial 75 mg/day, increases up to a maximum&nbsp;<br />dose of 225 mg/day may be considered. Dosage increases can be made at intervals of 2 weeks or more.<br />Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical<br />evaluation (see section 4.4). The lowest effective dose should be maintained.<br />Patients should be treated for a sufficient period of time, usually several months or longer. Treatment&nbsp;<br />should be reassessed regularly, on a case-by-case basis.<br /><strong>Use in elderly patients&nbsp;</strong><br />No specific dose adjustments of venlafaxine are considered necessary based on patient age alone.&nbsp;<br />However, caution should be exercised in treating the elderly (e.g., due to the possibility of renal&nbsp;<br />impairment, the potential for changes in neurotransmitter sensitivity and affinity occurring with aging).&nbsp;<br />The lowest effective dose should always be used, and patients should be carefully monitored when an&nbsp;<br />increase in the dose is required.&nbsp;<br /><strong>Use in children and adolescents under the age of 18 years</strong><br />Venlafaxine is not recommended for use in children and adolescents.&nbsp;<br />Controlled clinical studies in children and adolescents with major depressive disorder failed to&nbsp;<br />demonstrate efficacy and do not support the use of venlafaxine in these patients (see sections 4.4 and&nbsp;<br />4.8).&nbsp;<br />The efficacy and safety of venlafaxine for other indications in children and adolescents under the age of&nbsp;<br />18 have not been established.</p><p><strong>Use in patients with hepatic impairment&nbsp;</strong><br />In patients with mild and moderate hepatic impairment, in general a 50% dose reduction should be&nbsp;<br />considered. However, due to inter-individual variability in clearance, individualisation of dosage may&nbsp;<br />be desirable.&nbsp;<br />There are limited data in patients with severe hepatic impairment. Caution is advised, and a dose&nbsp;<br />reduction by more than 50% should be considered. The potential benefit should be weighed against the&nbsp;<br />risk in the treatment of patients with severe hepatic impairment.&nbsp;<br /><strong>Use in patients with renal impairment&nbsp;</strong><br />Although no change in dosage is necessary for patients with glomerular filtration rate (GFR) between&nbsp;<br />30-70 ml/minute, caution is advised. For patients that require haemodialysis and in patients with severe&nbsp;<br />renal impairment (GFR &lt; 30 ml/min), the dose should be reduced by 50%. Because of inter-individual&nbsp;<br />variability in clearance in these patients, individualisation of dosage may be desirable.&nbsp;<br /><strong>Withdrawal symptoms seen on discontinuation of venlafaxine&nbsp;</strong><br />Abrupt discontinuation should be avoided. When stopping treatment with venlafaxine, the dose should<br />be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal&nbsp;<br />reactions (see sections 4.4 and 4.8). If intolerable symptoms occur following a decrease in the dose or&nbsp;<br />upon discontinuation of treatment, then resuming the previously prescribed dose may be considered.&nbsp;<br />Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.&nbsp;<br />For oral use.&nbsp;<br />It is recommended that venlafaxine prolonged-release capsules be taken with food, at approximately the&nbsp;<br />same time each day. Capsules must be swallowed whole with fluid and not divided, crushed, chewed, or&nbsp;<br />dissolved.&nbsp;<br />Patients treated with venlafaxine immediate-release tablets may be switched to venlafaxine prolongedrelease capsules at the nearest equivalent daily dosage. For example, venlafaxine immediate-release&nbsp;<br />tablets 37.5 mg twice daily may be switched to venlafaxine prolonged-release capsules 75 mg once&nbsp;<br />daily. Individual dosage adjustments may be necessary.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients. 
Concomitant treatment with irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated due 
to the risk of serotonin syndrome with symptoms such as agitation, tremor and hyperthermia. 
Venlafaxine must not be initiated for at least 14 days after discontinuation of treatment with an 
irreversible MAOI.
Venlafaxine must be discontinued for at least 7 days before starting treatment with an irreversible 
MAOI (see sections 4.4 and 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Suicide/suicidal thoughts or clinical worsening&nbsp;</strong><br />Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide (suiciderelated events). This risk persists until significant remission occurs. As improvement may not occur&nbsp;<br />during the first few weeks or more of treatment, patients should be closely monitored until such&nbsp;<br />improvement occurs. It is general clinical experience that the risk of suicide may increase in the early&nbsp;<br />stages of recovery.&nbsp;<br />Other psychiatric conditions for which venlafaxine is prescribed can also be associated with an&nbsp;<br />increased risk of suicide-related events. In addition, these conditions may be co-morbid with major&nbsp;<br />depressive disorder. The same precautions observed when treating patients with major depressive&nbsp;<br />disorder should therefore be observed when treating patients with other psychiatric disorders.&nbsp;<br />Patients with a history of suicide-related events, or those exhibiting a si gnificant degree of suicidal&nbsp;<br />ideation prior to commencement of treatment, are known to be at greater risk of suicidal thoughts or&nbsp;<br />suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebocontrolled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an&nbsp;increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25&nbsp;<br />years old.&nbsp;<br />Close supervision of patients, and in particular those at high risk, should accompany drug therapy,&nbsp;<br />especially in early treatment and following dose changes. Patients (and caregivers of patients) should be&nbsp;<br />alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual&nbsp;<br />changes in behaviour, and to seek medical advice immediately if these symptoms present<br /><strong>Use in children and adolescents under 18 years of age&nbsp;</strong><br />[Product name] should not be used in the treatment of children and adolescents under the age of 18&nbsp;<br />years. Suicide-related behaviours (suicide attempt and suicidal thoughts) and hostility (predominantly&nbsp;<br />aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among&nbsp;<br />children and adolescents treated with antidepressants compared to those treated with placebo. If, based&nbsp;<br />on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for&nbsp;<br />the appearance of suicidal symptoms. In addition, long-term safety data in children and adolescents&nbsp;<br />concerning growth, maturation and cognitive and behavioural development are lacking.&nbsp;<br /><strong>Serotonin syndrome&nbsp;</strong><br />As with other serotonergic agents, serotonin syndrome, a potentially life-threatening condition, may&nbsp;<br />occur with venlafaxine treatment, particularly with concomitant use of other agents, such as MAO&nbsp;inhibitors, that may affect the serotonergic neurotransmitter systems (see sections 4.3 and 4.5).&nbsp;<br />Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations,&nbsp;<br />coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular&nbsp;<br />aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea,&nbsp;<br />vomiting, diarrhoea).&nbsp;<br /><strong>Narrow-angle glaucoma&nbsp;</strong><br />Mydriasis may occur in association with venlafaxine. It is recommended that patients with raised&nbsp;<br />intraocular pressure or patients at risk for acute narrow-angle glaucoma (angle-closure glaucoma) be&nbsp;<br />closely monitored.&nbsp;<br /><strong>Blood pressure&nbsp;</strong><br />Dose-related increases in blood pressure have been commonly reported with venlafaxine. In some&nbsp;<br />cases, severely elevated blood pressure requiring immediate treatment has been reported in&nbsp;<br />postmarketing experience. All patients should be carefully screened for high blood pressure and preexisting hypertension should be controlled before initiation of treatment. Blood pressure should be&nbsp;<br />reviewed periodically, after initiation of treatment and after dose increases. Caution should be exercised&nbsp;<br />in patients whose underlying conditions might be compromised by increases in blood pressure, e.g.,&nbsp;<br />those with impaired cardiac function.&nbsp;<br /><strong>Heart rate</strong><br />Increases in heart rate can occur, particularly with higher doses. Caution should be exercised in patients&nbsp;<br />whose underlying conditions might be compromised by increases in heart rate.&nbsp;<br /><strong>Cardiac disease and risk of arrhythmia&nbsp;</strong><br />Venlafaxine has not been evaluated in patients with a recent history of myocardial infarction or unstable&nbsp;<br />heart disease. Therefore, it should be used with caution in these patients.&nbsp;<br />In postmarketing experience, fatal cardiac arrhythmias have been reported with the use of venlafaxine,&nbsp;<br />especially in overdose. The balance of risks and benefits should be considered before prescribing&nbsp;<br />venlafaxine to patients at high risk of serious cardiac arrhythmia.&nbsp;<br /><strong>Convulsions&nbsp;</strong><br />Convulsions may occur with venlafaxine therapy. As with all antidepressants, venlafaxine should be&nbsp;<br />introduced with caution in patients with a history of convulsions, and concerned patients should be&nbsp;<br />closely monitored. Treatment should be discontinued in any patient who develops seizures.&nbsp;<br /><strong>Hyponatraemia</strong></p><p>Cases of hyponatraemia and/or the Syndrome of Inappropriate Antidiuretic Hormone (SIADH)&nbsp;<br />secretion may occur with venlafaxine. This has most frequently been reported in volume-depleted or&nbsp;<br />dehydrated patients. Elderly patients, patients taking diuretics, and patients who are otherwise volumedepleted may be at greater risk for this event.&nbsp;<br /><strong>Abnormal bleeding&nbsp;</strong><br />Medicinal products that inhibit serotonin uptake may lead to reduced platelet function. The risk of skin&nbsp;<br />and mucous membrane bleeding, including gastrointestinal haemorrhage, may be increased in patients&nbsp;<br />taking venlafaxine. As with other serotonin-reuptake inhibitors, venlafaxine should be used cautiously&nbsp;<br />in patients predisposed to bleeding, including patients on anticoagulants and platelet inhibitors.&nbsp;<br /><strong>Serum cholesterol&nbsp;</strong><br />Clinically relevant increases in serum cholesterol were recorded in 5.3% of venlafaxine-treated patients&nbsp;<br />and 0.0% of placebo-treated patients treated for at least 3 months in placebo-controlled clinical trials.&nbsp;<br />Measurement of serum cholesterol levels should be considered during long-term treatment.&nbsp;<br /><strong>Co-administration with weight loss agents&nbsp;</strong><br />The safety and efficacy of venlafaxine therapy in combination with weight loss agents, including&nbsp;<br />phentermine, have not been established. Co-administration of venlafaxine and weight loss agents is not&nbsp;<br />recommended. Venlafaxine is not indicated for weight loss alone or in combination with other products.&nbsp;<br /><strong>Mania/hypomania&nbsp;</strong><br />Mania/hypomania may occur in a small proportion of patients with mood disorders who have received&nbsp;<br />antidepressants, including venlafaxine. As with other antidepressants, venlafaxine should be used&nbsp;<br />cautiously in patients with a history or family history of bipolar disorder.&nbsp;<br /><strong>Aggression&nbsp;</strong><br />Aggression may occur in a sm all number of patients who have received antidepressants, including&nbsp;<br />venlafaxine. This has been reported under initiation, dose changes and discontinuation of treatment.&nbsp;<br />As with other antidepressants, venlafaxine should be used cautiously in patients with a history of&nbsp;<br />aggression.&nbsp;<br /><strong>Discontinuation of treatment&nbsp;</strong><br />Withdrawal symptoms, when treatment is discontinued, are common, particularly if discontinuation is&nbsp;<br />abrupt (see section 4.8). In clinical trials, adverse events seen on treatment discontinuation (tapering and&nbsp;<br />post-tapering) occurred in approximately 31% of patients treated with venlafaxine and 17% of patients&nbsp;<br />taking placebo.</p><p>The risk of withdrawal symptoms may be dependent on several factors, including the duration and dose&nbsp;<br />of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia),&nbsp;<br />sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or&nbsp;<br />vomiting, tremor and headache are the most commonly reported reactions. Generally, these symptoms&nbsp;<br />are mild to moderate; however, in some patients they may be severe in intensity. They usually occur&nbsp;<br />within the first few days of discontinuing treatment, but there have been very rare reports of such&nbsp;<br />symptoms in patients who have inadvertently missed a d ose. Generally, these symptoms are selflimiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3&nbsp;<br />months or more). It is therefore advised that venlafaxine should be gradually tapered when&nbsp;<br />discontinuing treatment over a period of several weeks or months, according to the patient&rsquo;s needs (see&nbsp;<br />section 4.2).&nbsp;<br /><strong>Akathisia/psychomotor restlessness&nbsp;</strong><br />The use of venlafaxine has been associated with the development of akathisia, characterised by a&nbsp;<br />subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability&nbsp;<br />to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who&nbsp;<br />develop these symptoms, increasing the dose may be detrimental.&nbsp;<br /><u>Dry mouth&nbsp;</u><br />Dry mouth is reported in 10% of patients treated with venlafaxine. This may increase the risk of caries,&nbsp;<br />and patients should be advised upon the importance of dental hygiene.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Monoamine Oxidase Inhibitors (MAOI)&nbsp;</strong><br />Irreversible non-selective MAOIs&nbsp;<br />Venlafaxine must not be used in combination with irreversible non-selective MAOIs. Venlafaxine must&nbsp;<br />not be initiated for at least 14 days after discontinuation of treatment with an irreversible nonselective&nbsp;<br />MAOI. Venlafaxine must be discontinued for at least 7 days before starting treatment with an&nbsp;<br />irreversible non-selective MAOI (see sections 4.3 and 4.4).&nbsp;<br /><strong>Reversible, selective MAO-A inhibitor (moclobemide)&nbsp;</strong><br />Due to the risk of serotonin syndrome, the combination of venlafaxine with a reversible and selective&nbsp;<br />MAOI, such as moclobemide, is not recommended. Following treatment with a reversible MAOinhibitor, a shorter withdrawal period than 14 da ys may be used before initiation of venlafaxine&nbsp;<br />treatment. It is recommended that venlafaxine should be discontinued for at least 7 days before starting&nbsp;<br />treatment with a reversible MAOI (see section 4.4).&nbsp;<br /><strong>Reversible, non-selective MAOI (linezolid)&nbsp;</strong><br />The antibiotic linezolid is a w eak reversible and non-selective MAOI and should not be given to&nbsp;patients treated with venlafaxine (see section 4.4).</p><p>Severe adverse reactions have been reported in patients who have recently been discontinued from an&nbsp;<br />MAOI and started on venlafaxine, or have recently had venlafaxine therapy discontinued prior to&nbsp;initiation of an MAOI. These reactions have included tremor, myoclonus, diaphoresis, nausea,&nbsp;vomiting, flushing, dizziness, and hyperthermia with features resembling neuroleptic malignant&nbsp;syndrome, seizures, and death.&nbsp;<br /><strong>Serotonin syndrome&nbsp;</strong><br />As with other serotonergic agents, serotonin syndrome may occur with venlafaxine treatment,&nbsp;<br />particularly with concomitant use of other agents that may affect the serotonergic neurotransmitter&nbsp;<br />system (including triptans, SSRIs, SNRIs, lithium, sibutramine, tramadol, or St. John&#39;s Wort&nbsp;<br />[Hypericum perforatum]), with medicinal agents which impair metabolism of serotonin (including&nbsp;<br />MAOIs), or with serotonin precursors (such as tryptophan supplements).&nbsp;<br />If concomitant treatment of venlafaxine with an SSRI, an SNRI or a serotonin receptor agonist (triptan)&nbsp;is clinically warranted, careful observation of the patient is advised, particularly during treatment&nbsp;initiation and dose increases. The concomitant use of venlafaxine with serotonin precursors (such as&nbsp;tryptophan supplements) is not recommended (see section 4.4).&nbsp;<br /><strong>CNS-active substances&nbsp;</strong><br />The risk of using venlafaxine in combination with other CNS-active substances has not been&nbsp;<br />systematically evaluated. Consequently, caution is advised when venlafaxine is taken in combination&nbsp;<br />with other CNS-active substances.&nbsp;<br /><strong>Ethanol&nbsp;</strong><br />Venlafaxine has been shown not to increase the impairment of mental and motor skills caused by&nbsp;<br />ethanol. However, as with all CNS-active substances, patients should be advised to avoid alcohol&nbsp;<br />consumption.&nbsp;<br /><strong>Effect of other medicinal products on venlafaxine&nbsp;</strong><br /><strong>Ketoconazole (CYP3A4 inhibitor)&nbsp;</strong><br />A pharmacokinetic study with ketoconazole in CYP2D6 extensive (EM) and poor metabolisers (PM)&nbsp;resulted in higher AUC of venlafaxine (70% and 21% in CYP2D6 PM and EM subjects, respectively)&nbsp;and O-desmethylvenlafaxine (33% and 23% in CYP2D6 PM and EM subjects, respectively) following&nbsp;administration of ketoconazole. Concomitant use of CYP3A4 inhibitors (e.g., atazanavir,&nbsp;clarithromycin, indinavir, itraconazole, voriconazole, posaconazole, ketoconazole, nelfinavir, ritonavir,&nbsp;saquinavir, telithromycin) and venlafaxine may increase levels of venlafaxine and Odesmethylvenlafaxine. Therefore, caution is advised if a patient&rsquo;s therapy includes a CYP3A4 inhibitor&nbsp;and venlafaxine concomitantly.&nbsp;<br /><strong>Effect of venlafaxine on other medicinal products&nbsp;<br />Lithium&nbsp;</strong><br />Serotonin syndrome may occur with the concomitant use of venlafaxine and lithium (see Serotonin&nbsp;syndrome).&nbsp;</p><p><strong>Diazepam</strong>&nbsp;<br />Venlafaxine has no effects on the pharmacokinetics and pharmacodynamics of diazepam and its active&nbsp;metabolite, desmethyldiazepam. Diazepam does not appear to affect the pharmacokinetics of either&nbsp;venlafaxine or O-desmethylvenlafaxine. It is unknown whether a pharmacokinetic and/or&nbsp;pharmacodynamic interaction with other benzodiazepines exists.&nbsp;</p><p><br /><strong>Imipramine</strong></p><p>&nbsp;Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine. There was a&nbsp;dose-dependent increase of 2-OH-desipramine AUC by 2.5 to 4.5-fold when venlafaxine 75 mg to 150&nbsp;mg daily was administered. Imipramine did not affect the pharmacokinetics of venlafaxine and Odesmethylvenlafaxine. The clinical significance of this interaction is unknown. Caution should be&nbsp;exercised with co-administration of venlafaxine and imipramine.&nbsp;<br />&nbsp;<br /><strong>Haloperidol&nbsp;</strong><br />A pharmacokinetic study with haloperidol has shown a 42% decrease in total oral clearance, a 70%&nbsp;increase in AUC, an 88% increase in Cmax, but no change in half-life for haloperidol. This should be&nbsp;taken into account in patients treated with haloperidol and venlafaxine concomitantly. The clinical&nbsp;significance of this interaction is unknown.&nbsp;<br /><strong>Risperidone&nbsp;</strong></p><p>Venlafaxine increased the risperidone AUC by 50%, but did not significantly alter the pharmacokinetic&nbsp;<br />profile of the total active moiety (risperidone plus 9-hydroxyrisperidone). The clinical significance of&nbsp;this interaction is unknown.&nbsp;</p><p><br /><strong>Metoprolol&nbsp;</strong><br />Concomitant administration of venlafaxine and metoprolol to healthy volunteers in a pharmacokinetic&nbsp;<br />interaction study for both medicinal products resulted in an increase of plasma concentrations of&nbsp;metoprolol by approximately 30-40% without altering the plasma concentrations of its active&nbsp;<br />metabolite, &alpha;-hydroxymetoprolol. The clinical relevance of this finding in hypertensive patients is&nbsp;unknown. Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite,&nbsp;<br />O-desmethylvenlafaxine. Caution should be exercised with co-administration of venlafaxine and&nbsp;metoprolol.&nbsp;</p><p><br /><strong>Indinavir&nbsp;</strong><br />A pharmacokinetic study with indinavir has shown a 28% decrease in AUC and a 36% decrease in Cmaxfor indinavir. Indinavir did not affect the pharmacokinetics of venlafaxine and O-desmethylvenlafaxine.&nbsp;The clinical significance of this interaction is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy&nbsp;</strong><br />There are no adequate data from the use of venlafaxine in pregnant women.&nbsp;<br />Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is&nbsp;unknown. Venlafaxine must only be administered to pregnant women if the expected benefits outweigh&nbsp;any possible risk.&nbsp;<br />As with other serotonin reuptake inhibitors (SSRIs/SNRIs), discontinuation symptoms may occur in the&nbsp;newborns if venlafaxine is used until or shortly before birth. Some newborns exposed to venlafaxine&nbsp;late in the third trimester have developed complications requiring tube-feeding, respiratory support or&nbsp;prolonged hospitalisation. Such complications can arise immediately upon delivery.&nbsp;<br />Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late&nbsp;<br />pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN).&nbsp;Although no s tudies have investigated an association of PPHN to SNRI treatment, this&nbsp;potential risk cannot be ruled out with [Product name] t aking into account the related&nbsp;<br />mechanism of action (inhibition of the re-uptake of serotonin).&nbsp;<br />The following symptoms may be observed in neonates if the mother has used an SSRI/SNRI late in&nbsp;pregnancy: irritability, tremor, hypotonia, persistent crying, and difficulty in sucking or in sleeping.&nbsp;<br />These symptoms may be due to either serotonergic effects or exposure symptoms. In the majority of&nbsp;cases, these complications are observed immediately or within 24 hours after partus.&nbsp;<br /><strong>Lactation&nbsp;</strong><br />Venlafaxine and its active metabolite, O-desmethylvenlafaxine, are excreted in breast milk. A risk to&nbsp;the suckling child cannot be excluded. Therefore, a decision to continue/discontinue breast-feeding or to&nbsp;continue/discontinue therapy with [Product name] should be made, taking into account the benefit of&nbsp;breast-feeding to the child and the benefit of [Product name] therapy to the woman.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any psychoactive medicinal product may impair judgment, thinking, and motor skills. Therefore, any&nbsp;patient receiving venlafaxine should be cautioned about their ability to drive or operate hazardous&nbsp;machinery.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly (&gt;1/10) reported adverse reactions in clinical studies were nausea, dry mouth, headache and sweating (including night sweats). &nbsp;<br />&nbsp;<br />Adverse reactions are listed below by system organ class and frequency. &nbsp;<br />&nbsp;<br />Frequencies are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), not known (cannot be estimated from the available data). &nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:1367px"><tbody><tr><td style="vertical-align:top; width:83px"><p><strong>Body System</strong></p></td><td style="vertical-align:top; width:98px"><p><strong>Very Common</strong></p></td><td style="vertical-align:top; width:346px"><p><strong>Common</strong></p></td><td style="vertical-align:top; width:182px"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top; width:154px"><p><strong>Rare</strong></p></td><td style="vertical-align:top; width:478px"><p><strong>Not Known</strong></p></td></tr><tr><td style="vertical-align:top; width:83px"><p>Haematological</p><p>/ Lymphatic</p></td><td style="vertical-align:top; width:98px"><p>&nbsp;</p></td><td style="vertical-align:top; width:346px"><p>&nbsp;</p></td><td style="vertical-align:top; width:182px"><p>Ecchymosis,</p><p>Gastrointestinal</p></td><td style="vertical-align:top; width:154px"><p>&nbsp;</p></td><td style="vertical-align:top; width:478px"><p>Mucous</p><p>membrane]</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:107px"><p>&nbsp;</p></td><td style="vertical-align:top; width:98px"><p>&nbsp;</p></td><td style="vertical-align:top; width:342px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>haemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>bleeding, Prolonged bleeding&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; time, Thrombocytopa enia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood dyscrasias, (including agranulocytosis, aplastic anaemia, neutropaenia and</p><p>pancytopaenia)</p></td></tr><tr><td style="vertical-align:top; width:107px"><p>Metabolic/ Nutritional</p></td><td style="vertical-align:top; width:98px"><p>&nbsp;</p></td><td style="vertical-align:top; width:342px"><p>Serum cholesterol increased, Weight loss</p></td><td style="vertical-align:top"><p>Weight gain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abnormal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver function&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tests, Hyponatraemia, Hepatitis, Syndrome&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of Inappropriate Antidiuretic Hormone Secretion (SIADH),</p><p>Prolactin</p><p>increased</p></td></tr><tr><td style="vertical-align:top; width:107px"><p>Nervous</p></td><td style="vertical-align:top; width:98px"><p>Dry mouth (10.0%),</p><p>Headache (30.3%)*</p></td><td style="vertical-align:top; width:342px"><p>Abnormal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dreams, Decreased&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; libido, Dizziness, Increased muscle&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tonus (hypertonia), Insomnia, Nervousness, Paresthesia, Sedation,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tremor, Confusion, Depersonalisation</p></td><td style="vertical-align:top"><p>Apathy, Hallucinations, Myoclonus, Agitation, Impaired coordination and balance</p></td><td style="vertical-align:top"><p>Akathisia/ Psychomoto r restlessness, Convulsion, Manic reaction</p></td><td style="vertical-align:top"><p>Neuroleptic Malignant Syndrome (NMS),</p><p>Serotonergic syndrome, Delirium, Extrapyramidal reactions (including dystonia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and dyskinaesia), Tardive dyskinaesia, Suicidal ideation and</p><p>behaviours**</p></td></tr><tr><td style="vertical-align:top; width:107px"><p>Special Senses</p></td><td style="vertical-align:top; width:98px"><p>&nbsp;</p></td><td style="vertical-align:top; width:342px"><p>Abnormality&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of accommodation, Mydriasis,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visual</p><p>disturbance,</p></td><td style="vertical-align:top"><p>Altered&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; taste sensation, Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angle-closure glaucoma</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Cardiovascular</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypertension, Vasodilatation (mostly hot flashes/flushes), Palpitations</p></td><td style="vertical-align:top; width:6px"><p>&nbsp;</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:243.359px"><p>Postural hypotension, Syncope, Tachycardia&nbsp; &nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top; width:85.6406px"><p>&nbsp;</p></td><td style="vertical-align:top; width:274px"><p>Hypotension, QT</p><p>prolongation, Ventricular fibrillation, Ventricular tachycardia (including torsade&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; de</p><p>pointes)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Respiratory</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:273px"><p>Yawning</p></td><td colspan="2" style="vertical-align:top; width:243.359px"><p>&nbsp;</p></td><td style="vertical-align:top; width:85.6406px"><p>&nbsp;</p></td><td style="vertical-align:top; width:274px"><p>Pulmonary</p><p>eosinophilia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Digestive</p></td><td style="vertical-align:top"><p>Nausea (20.0%)</p></td><td colspan="2" style="vertical-align:top; width:273px"><p>Appetite&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased (anorexia), Constipation,</p><p>Vomiting</p></td><td colspan="2" style="vertical-align:top; width:243.359px"><p>Bruxism, Diarrhoea</p></td><td style="vertical-align:top; width:85.6406px"><p>&nbsp;</p></td><td style="vertical-align:top; width:274px"><p>Pancreatitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Skin</p></td><td style="vertical-align:top"><p>Sweating (including night sweats) [12.2%]</p></td><td colspan="2" style="vertical-align:top; width:273px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:243.359px"><p>Rash, Alopecia</p></td><td style="vertical-align:top; width:85.6406px"><p>&nbsp;</p></td><td style="vertical-align:top; width:274px"><p>Erythema multiforme, Toxic epidermal necrolysis, Stevens-Johnson syndrome, Pruritus,</p><p>Urticaria</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Musculoskeletal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:273px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:243.359px"><p>&nbsp;</p></td><td style="vertical-align:top; width:85.6406px"><p>&nbsp;</p></td><td style="vertical-align:top; width:274px"><p>Rhabdomyolysis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Urogenital</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:273px"><p>Abnormal ejaculation/orgasm (males), Anorgasmia, Erectile dysfunction (impotence), Urination&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired (mostly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hesitancy), Menstrual disorders associated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with increased&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased irregular&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding (e.g.,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; menorrhagia, metrorrhagia),</p><p>Pollakiuria</p></td><td colspan="2" style="vertical-align:top; width:243.359px"><p>Abnormal orgasm (females), Urinary retention</p></td><td style="vertical-align:top; width:85.6406px"><p>&nbsp;</p></td><td style="vertical-align:top; width:274px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Body as a</p><p>Whole</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:273px"><p>Asthenia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (fatigue),</p><p>Chills</p></td><td style="vertical-align:top; width:243px"><p>Photosensitivity</p><p>reaction</p></td><td style="vertical-align:top; width:1px">&nbsp;</td><td style="vertical-align:top; width:85.6406px"><p>&nbsp;</p></td><td style="vertical-align:top; width:274px"><p>Anaphylaxis</p></td></tr></tbody></table><p>*In pooled clinical trials, the incidence of headache was 30.3% with venlafaxine versus 31.3% with&nbsp;placebo.</p><p>**Cases of suicidal ideation and suicidal behaviours have been reported during venlafaxine therapy or&nbsp;early after treatment discontinuation (see section 4.4).&nbsp;Discontinuation of venlafaxine (particularly when abrupt) commonly leads to withdrawal symptoms.&nbsp;Dizziness, sensory disturbances (including paraethesia), sleep disturbances (including insomnia and&nbsp;intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, headache and flu syndrome are&nbsp;<br />the most commonly reported reactions. Generally, these events are mild to moderate and are selflimiting; however, in some patients, they may be severe and/or prolonged. It is therefore advised that&nbsp;<br />when venlafaxine treatment is no longer required, gradual discontinuation by dose tapering should be&nbsp;carried out (see sections 4.2 and 4.4).&nbsp;<br /><strong>Paediatric patients&nbsp;</strong></p><p>In general, the adverse reaction profile of venlafaxine (in placebo-controlled clinical trials) in children&nbsp;<br />and adolescents (ages 6 to 17) was similar to that seen for adults. As with adults, decreased appetite,&nbsp;<br />weight loss, increased blood pressure, and increased serum cholesterol were observed (see section 4.4).&nbsp;<br />In paediatric clinical trials the adverse reaction suicidal ideation was observed. There were also&nbsp;increased reports of hostility and, especially in major depressive disorder, self-harm.&nbsp;Particularly, the following adverse reactions were observed in paediatric patients: abdominal pain,&nbsp;agitation, dyspepsia, ecchymosis, epistaxis, and myalgia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In postmarketing experience, overdose with venlafaxine was reported predominantly in combination&nbsp;with alcohol and/or other medicinal products. The most commonly reported events in overdose include&nbsp;tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis,&nbsp;convulsion, and vomiting. Other reported events include electrocardiographic changes (e.g.,&nbsp;prolongation of QT interval, bundle branch block, QRS prolongation), ventricular tachycardia,&nbsp;bradycardia, hypotension, vertigo, and death.&nbsp;<br />Published retrospective studies report that venlafaxine overdosage may be associated with an increased&nbsp;risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that&nbsp;for tricyclic antidepressants. Epidemiological studies have shown that venlafaxine-treated patients have&nbsp;a higher burden of suicide risk factors than SSRI patients. The extent to which the finding of an&nbsp;increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdosage, as&nbsp;opposed to some characteristics of venlafaxine-treated patients, is not clear. Prescriptions for&nbsp;venlafaxine should be written for the smallest quantity of the medicinal product consistent with good&nbsp;patient management in order to reduce the risk of overdose.&nbsp;</p><p><br /><strong>Recommended treatment&nbsp;</strong><br />General supportive and symptomatic measures are recommended; cardiac rhythm and vital signs must&nbsp;be monitored. When there is a risk of aspiration, induction of emesis is not recommended. Gastric&nbsp;lavage may be indicated if performed soon after ingestion or in symptomatic patients. Administration of&nbsp;activated charcoal may also limit absorption of the active substance. Forced diuresis, dialysis,&nbsp;hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific antidotes for&nbsp;<br />venlafaxine are known.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1 Pharmacodynamic properties&nbsp;<br />Pharmacotherapeutic group: Other antidepressants - ATC code: NO6A X16.&nbsp;<br />The mechanism of venlafaxine&#39;s antidepressant action in humans is believed to be associated with its&nbsp;<br />potentiation of neurotransmitter activity in the central nervous system. Preclinical studies have shown&nbsp;<br />that venlafaxine and its major metabolite, O-desmethylvenlafaxine (ODV), are inhibitors of serotonin&nbsp;<br />and noradrenaline reuptake. Venlafaxine also weakly inhibits dopamine uptake. Venlafaxine and its&nbsp;<br />active metabolite reduce &beta;-adrenergic responsiveness after both acute (single dose) and chronic&nbsp;<br />administration. Venlafaxine and ODV are very similar with respect to their overall action on&nbsp;<br />neurotransmitter reuptake and receptor binding.&nbsp;<br />Venlafaxine has virtually no a ffinity for rat brain muscarinic, cholinergic, H1-histaminergic or &alpha;1-<br />adrenergic receptors in vitro. Pharmacological activity at these receptors may be related to various side&nbsp;<br />effects seen with other antidepressant medicinal products, such as anticholinergic, sedative and&nbsp;<br />cardiovascular side effects.&nbsp;<br />&nbsp;<br />Venlafaxine does not possess monoamine oxidase (MAO) inhibitory activity.&nbsp;<br />In vitro studies revealed that venlafaxine has virtually no affinity for opiate or benzodiazepine sensitive&nbsp;<br />receptors.&nbsp;<br /><strong>Major depressive episodes&nbsp;</strong><br />The efficacy of venlafaxine immediate-release as a treatment for major depressive episodes was&nbsp;<br />demonstrated in five randomised, double-blind, placebo-controlled, short-term trials ranging from 4 to 6&nbsp;<br />weeks duration, for doses up t o 375 m g/day. The efficacy of venlafaxine prolonged-release as a&nbsp;<br />treatment for major depressive episodes was established in two placebo-controlled, short-term studies&nbsp;<br />for 8 and 12 weeks duration, which included a dose range of 75 to 225 mg/day.&nbsp;<br />In one longer-term study, adult outpatients who had responded during an 8-week open trial on&nbsp;<br />venlafaxine prolonged-release (75, 150, o r 225 m g) were randomised to continuation of their same&nbsp;<br />venlafaxine prolonged-release dose or to placebo, for up to 26 weeks of observation for relapse.&nbsp;<br />In a second longer-term study, the efficacy of venlafaxine in prevention of recurrent depressive&nbsp;<br />episodes for a 12-month period was established in a placebo-controlled double-blind clinical trial in&nbsp;<br />adult outpatients with recurrent major depressive episodes who had responded to venlafaxine treatment&nbsp;<br />(100 to 200 mg/day, on a b.i.d. schedule) on the last episode of depression.&nbsp;<br /><strong>Social anxiety disorder&nbsp;</strong><br />The efficacy of venlafaxine prolonged-release capsules as a treatment for social anxiety disorder was&nbsp;<br />established in four double-blind, parallel-group, 12-week, multi-center, placebo-controlled, flexible&nbsp;dose studies and one double-blind, parallel-group, 6-month, placebo-controlled, fixed/flexible-dose&nbsp;<br />study in adult outpatients. Patients received doses in a range of 75 to 225 mg/day. There was no&nbsp;<br />evidence for any greater effectiveness of the 150 to 225 mg/day group compared to the 75 m g/day&nbsp;<br />group in the 6-month study.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Venlafaxine is extensively metabolised, primarily to the active metabolite, O-desmethylvenlafaxine&nbsp;<br />(ODV). Mean &plusmn; SD plasma half-lives of venlafaxine and ODV are 5&plusmn;2 hours and 11&plusmn;2 hours,&nbsp;<br />respectively. Steady-state concentrations of venlafaxine and ODV are attained within 3 days of oral&nbsp;<br />multiple-dose therapy. Venlafaxine and ODV exhibit linear kinetics over the dose range of 75 mg to&nbsp;<br />450 mg/day.&nbsp;<br /><strong>Absorption&nbsp;</strong><br />At least 92% of venlafaxine is absorbed following single oral doses of immediate-release venlafaxine.&nbsp;<br />Absolute bioavailability is 40% to 45% due to presystemic metabolism. After immediate-release&nbsp;<br />venlafaxine administration, the peak plasma concentrations of venlafaxine and ODV occur in 2 and 3&nbsp;<br />hours, respectively. Following the administration of venlafaxine prolonged-release capsules, peak&nbsp;<br />plasma concentrations of venlafaxine and ODV are attained within 5.5 hours and 9 hours, respectively.&nbsp;<br />When equal daily doses of venlafaxine are administered as either an immediate-release tablet or&nbsp;<br />prolonged-release capsule, the prolonged-release capsule provides a slower rate of absorption, but the&nbsp;<br />same extent of absorption compared with the immediate-release tablet. Food does not affect the&nbsp;<br />bioavailability of venlafaxine and ODV.&nbsp;<br /><strong>Distribution&nbsp;</strong><br />Venlafaxine and ODV are minimally bound a t therapeutic concentrations to human plasma proteins&nbsp;<br />(27% and 30%, respectively). The volume of distribution for venlafaxine at steady-state is 4.4&plusmn;1.6 L/kg&nbsp;<br />following intravenous administration.&nbsp;<br /><strong>Metabolism&nbsp;</strong><br />Venlafaxine undergoes extensive hepatic metabolism. In vitro and in vivo studies indicate that&nbsp;<br />venlafaxine is biotransformed to its major active metabolite, ODV, by CYP2D6. In vitro and in vivo&nbsp;<br />studies indicate that venlafaxine is metabolised to a m inor, less active metabolite, Ndesmethylvenlafaxine, by CYP3A4. In vitro and in vivo studies indicate that venlafaxine is a weak&nbsp;<br />inhibitor of CYP2D6. Venlafaxine did not inhibit CYP1A2, CYP2C9, or CYP3A4.&nbsp;<br /><strong>Elimination&nbsp;</strong><br />Venlafaxine and its metabolites are excreted primarily through the kidneys. Approximately 87% of a&nbsp;<br />venlafaxine dose is recovered in the urine within 48 hours as either unchanged venlafaxine (5%),&nbsp;<br />unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%). Mean &plusmn;&nbsp;<br />SD plasma steady-state clearances of venlafaxine and ODV are 1.3&plusmn;0.6 L/h/kg and 0.4&plusmn;0.2 L/h/kg,&nbsp;<br />respectively.&nbsp;</p><p>&nbsp;</p><p><strong>Special populations&nbsp;<br />Age and gender&nbsp;</strong><br />Subject age and gender do not significantly affect the pharmacokinetics of venlafaxine and ODV.&nbsp;<br /><strong>CYP2D6 extensive/poor metabolisers&nbsp;</strong><br />Plasma concentrations of venlafaxine are higher in CYP2D6 poor metabolisers than extensive&nbsp;<br />metabolisers. Because the total exposure (AUC) of venlafaxine and ODV is similar in poor and&nbsp;<br />extensive metabolisers, there is no need for different venlafaxine dosing regimens for these two&nbsp;<br />groups.&nbsp;<br /><strong>Patients with hepatic impairment&nbsp;</strong><br />In Child-Pugh A (mildly hepatically impaired) and Child-Pugh B (moderately hepatically impaired)&nbsp;<br />subjects, venlafaxine and ODV half-lives were prolonged compared to normal subjects. The oral&nbsp;<br />clearance of both venlafaxine and ODV was reduced. A large degree of intersubject variability was&nbsp;<br />noted. There are limited data in patients with severe hepatic impairment (see section 4.2).&nbsp;<br /><strong>Patients with renal impairment&nbsp;</strong><br />In dialysis patients, venlafaxine elimination half-life was prolonged by about 180% and clearance&nbsp;<br />reduced by about 57% compared to normal subjects, while ODV elimination halflife was prolonged by&nbsp;<br />about 142% and clearance reduced by about 56%. Dosage adjustment is necessary in patients with&nbsp;<br />severe renal impairment and in patients that require haemodialysis (see section 4.2)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies with venlafaxine in rats and mice revealed no evidence of carcinogenesis. Venlafaxine was not&nbsp;<br />mutagenic in a wide range of in vitro and in vivo tests.<br />Animal studies regarding reproductive toxicity have found in rats a decrease in pup weight, an increase&nbsp;<br />in stillborn pups, and an increase in pup deaths during the first 5 days of lactation. The cause of these&nbsp;<br />deaths is unknown. These effects occurred at 30 mg/kg/day, 4 times the human daily dose of 375 mg of&nbsp;<br />venlafaxine (on an mg/kg basis). The no-effect dose for these findings was 1.3 times the human dose.&nbsp;<br />The potential risk for humans is unknown.&nbsp;<br />Reduced fertility was observed in a study in which both male and female rats were exposed to ODV.&nbsp;<br />This exposure was approximately 1 to 2 times that of a human venlafaxine dose of 375 mg/day. The&nbsp;<br />human relevance of this finding is unknown.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>75 mg prolonged-release capsules, hard:</u></em><br />Capsule content:&nbsp;<br />Hypromellose&nbsp;<br />Ammonio methacrylate copolymer (type B)<br />Sodium larilsulfate</p><p>Magnesium stearate<br />Coating:&nbsp;<br />Basic butylated methacrylate copolymer 12.5%&nbsp;<br />Capsule shell:&nbsp;<br />Gelatin<br />Titanium dioxide (E 171)&nbsp;<br />Red iron oxide (E172)&nbsp;<br />Printing ink:<br />Shellac<br />Black iron oxide (E172)&nbsp;<br />Propylene glycol (E1520)</p><p><br /><em><u>150 mg prolonged-release capsules, hard:</u></em><br />Capsule content:&nbsp;<br />Hypromellose&nbsp;<br />Ammonio methacrylate copolymer (type B)<br />Sodium larilsulfate&nbsp;<br />Magnesium stearate<br />Coating:&nbsp;<br />Basic butylated methacrylate copolymer 12.5%&nbsp;<br />Capsule shell:&nbsp;<br />Gelatin<br />Titanium dioxide (E 171)&nbsp;<br />Erythrosine (E127)<br />Indigotin I (E 132)&nbsp;<br />Printing ink:<br />Shellac<br />Black iron oxide (E172)&nbsp;<br />Propylene glycol (E1520)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PE/PVDC/Al blister<br />37.5 mg: 10, 14, 28, 30 and 98 prolonged-release capsules, hard&nbsp;<br />75 mg: 10, 14, 28, 30, 60 and 98 prolonged-release capsules, hard&nbsp;<br />150 mg: 10, 14, 28, 30, 60 and 98 prolonged-release capsules, hard&nbsp;<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
AlQassim pharmaceutical plant
 Saudi Pharmaceutical Industries & Medical Appliance Corporation. 
Saudi Arabia.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2012
 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>